CA2368467A1 - 50 proteines humaines secretees - Google Patents
50 proteines humaines secretees Download PDFInfo
- Publication number
- CA2368467A1 CA2368467A1 CA002368467A CA2368467A CA2368467A1 CA 2368467 A1 CA2368467 A1 CA 2368467A1 CA 002368467 A CA002368467 A CA 002368467A CA 2368467 A CA2368467 A CA 2368467A CA 2368467 A1 CA2368467 A1 CA 2368467A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- human
- sequence
- polypeptide
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
L'invention porte sur 50 nouvelles protéines humaines sécrétées et sur des acides nucléiques isolés comportant les régions codantes des gènes codant pour lesdites protéines. L'invention porte également sur des vecteurs, cellules hôtes, anticorps, et méthodes de recombinaison servant à produire lesdites protéines humaines sécrétées; elle porte en outre sur des procédés diagnostiques et thérapeutiques permettant de diagnostiquer et traiter les affections liées auxdites nouvelles protéines humaines sécrétées.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12659499P | 1999-03-26 | 1999-03-26 | |
US60/126,594 | 1999-03-26 | ||
US17240899P | 1999-12-17 | 1999-12-17 | |
US60/172,408 | 1999-12-17 | ||
PCT/US2000/007507 WO2000058334A1 (fr) | 1999-03-26 | 2000-03-22 | 50 proteines humaines secretees |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2368467A1 true CA2368467A1 (fr) | 2000-10-05 |
Family
ID=26824837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002368467A Abandoned CA2368467A1 (fr) | 1999-03-26 | 2000-03-22 | 50 proteines humaines secretees |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1173462A1 (fr) |
JP (1) | JP2002539814A (fr) |
CA (1) | CA2368467A1 (fr) |
WO (1) | WO2000058334A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1539228B1 (fr) | 2002-09-11 | 2010-12-29 | Genentech, Inc. | Nouvelles composition et methodes servant au traitement de maladies associees au systeme immunitaire |
CA2497334A1 (fr) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire |
WO2006124667A2 (fr) | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Compositions et procedes permettant de moduler des reponses immunitaires |
US20090258013A1 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
RS60826B1 (sr) | 2013-07-16 | 2020-10-30 | Hoffmann La Roche | Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora |
JP6920194B2 (ja) | 2014-08-19 | 2021-08-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗tigit抗体 |
AU2016307845B2 (en) | 2015-08-14 | 2020-10-15 | Merck Sharp & Dohme Llc | Anti-TIGIT antibodies |
RU2732591C2 (ru) | 2015-09-25 | 2020-09-21 | Дженентек, Инк. | Анти-tigit антитела и способы применения |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559026A (en) * | 1994-10-31 | 1996-09-24 | American Cyanamid Company | Genes encoding a novel family of potassium channels |
-
2000
- 2000-03-22 JP JP2000608034A patent/JP2002539814A/ja not_active Withdrawn
- 2000-03-22 CA CA002368467A patent/CA2368467A1/fr not_active Abandoned
- 2000-03-22 EP EP00921422A patent/EP1173462A1/fr not_active Withdrawn
- 2000-03-22 WO PCT/US2000/007507 patent/WO2000058334A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1173462A1 (fr) | 2002-01-23 |
WO2000058334A1 (fr) | 2000-10-05 |
JP2002539814A (ja) | 2002-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2368068A1 (fr) | 27 proteines humaines secretees | |
CA2368927A1 (fr) | Quarante-cinq proteines humaines secretees | |
CA2364209A1 (fr) | 49 proteines secretees humaines | |
CA2387696A1 (fr) | 48 proteines humaines secretees | |
CA2364630A1 (fr) | 50 proteines humaines secretees | |
CA2365223A1 (fr) | Proteines humaines secretees (46) | |
CA2368281A1 (fr) | 50 proteines humaines secretees | |
CA2368467A1 (fr) | 50 proteines humaines secretees | |
EP1173477A1 (fr) | 49 proteines humaines secretees | |
CA2391364A1 (fr) | 47 proteines humaines secretees | |
CA2368302A1 (fr) | 49 proteines secretees par un etre humain | |
CA2364635A1 (fr) | 47 proteines humaines secretees | |
CA2365522A1 (fr) | 48 proteines secretees humaines | |
CA2370441A1 (fr) | 50 proteines humaines secretees | |
CA2391361A1 (fr) | 47 proteines secretees humaines | |
CA2390946A1 (fr) | 49 proteines secretees humaines | |
CA2368442A1 (fr) | 48 proteines humaines secretees | |
CA2365247A1 (fr) | Proteines humaines secretees (49) | |
CA2368374A1 (fr) | 47 proteines humaines secretees | |
CA2368719A1 (fr) | Cinquante proteines humaines secretees | |
CA2364650A1 (fr) | Proteines humaines secretees (50) | |
CA2368700A1 (fr) | Quarante-neuf proteines humaines secretees | |
CA2368210A1 (fr) | Cinquante proteines humaines secretees | |
CA2368916A1 (fr) | 49 proteines humaines secretees | |
CA2367620A1 (fr) | Proteines humaines secretees (47) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |